ABLX.BR
Ablynx NV
Brussels
12.37-0.01 (-0.08%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close12.38
Open12.35
Bid11.21 x 30000
Ask11.89 x 150000
52wk Range10.00 - 16.20
Day's Range12.35 - 12.44
Volume26,086
Avg Vol (3m)203,492
As of 5:58 AM EDT. Brussels Delayed Price. Market open.
  • Reuters3 months ago

    Ablynx burns more cash in Q1 on higher R&D costs

    Belgian biotech firm Ablynx said on Thursday it used up more cash than it made in the first quarter, driven by higher external research and development costs. Cash burn is a closely watched figure for rising biotech companies that generate revenue only from development milestone payments, and not drug sales. The group, which makes treatments based on nanobodies, reported a net cash outflow of 2.5 million euros ($2.9 million) in the quarter and had remaining cash and cash equivalents of 233.7 million euros.

  • Reuters11 months ago

    Ablynx burns more cash in first half of 2015

    Belgian biotech firm Ablynx burnt through more cash in the first half of 2015, as it increased spending on research and clinical trials for its experimental drugs. Ablynx added it would bring its treatment for the rare blood disorder acquired thrombotic thrombocytopenic purpura to the market itself, without the partnership of a large pharma company. The drug, caplacizumab, would soon enter final clinical trials, which should be concluded in 2017, Ablynx added.